George W. Lloyd - 16 May 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: EVP, Investments & CLO
Issuer ticker: RPRX
Reported as of: 16 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2025, 16:51:00 UTC
Prior SEC filing: 09 May 2025
Next SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd

Key filing fact

George W. Lloyd filed Form 4 for Royalty Pharma plc (RPRX) on 20 May 2025.

Key facts

This page summarizes George W. Lloyd's Form 4 filing for Royalty Pharma plc (RPRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 May 2025, 16:51.

Change

Previous filing in this sequence was filed on 09 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814899 Primary reporting owner

Lloyd George W.

Relationship: EVP, Investments & CLO
Address: C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd
Signature date: 20 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RPRX transaction Derivative

Class E Ordinary Shares

Award

Transaction value: $0
Shares: +1,944,471
Change %
Price: $0.000000
Shares after: 1,944,471
Date: 16 May 2025
Ownership: See Footnote (1)(2)
Underlying class: Class A Ordinary Shares
Underlying amount: 1,944,471
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

Footnote F2

Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.